
Arena Pharma's Olorinab Fails To Top Placebo In IBS-Related Abdominal Pain
Arena Pharmaceuticals Inc (NASDAQ: ARNA) has announced topline data from Phase 2b CAPTIVATE trial evaluating olorinab for abdominal pain due to Irritable Bowel Syndrome (IBS). Although olorinab was well tolerated, the results show that it did not meet the …